SG Americas Securities LLC Lowers Stock Holdings in Moderna, Inc. $MRNA

SG Americas Securities LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,868 shares of the company’s stock after selling 27,930 shares during the period. SG Americas Securities LLC’s holdings in Moderna were worth $12,744,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. MUFG Securities EMEA plc purchased a new position in Moderna during the 2nd quarter worth $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Moderna in the 4th quarter worth $31,000. Ameriflex Group Inc. grew its position in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after buying an additional 1,208 shares in the last quarter. Cromwell Holdings LLC grew its position in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after buying an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after buying an additional 801 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s Science Day showcased an expanded pipeline that includes oncology, autoimmune disease, and next-generation mRNA programs, including a new in vivo CAR-T approach and T-cell engager candidates. Investors appear to be re-rating the stock on the prospect of multiple future commercial franchises beyond vaccines. Article
• Positive Sentiment: FDA advisory support for Moderna’s mRNA flu shot, mFlusiva, strengthened the case that its platform can win approvals outside COVID-19, potentially opening a second major commercial opportunity in respiratory vaccines for older adults. Article
• Positive Sentiment: Market commentary highlighted Moderna’s new cell therapy program and broader Science Day disclosures as the main reasons the stock is leading the market higher, with investors responding to signs that the company is building a more diversified biotech story. Article
• Neutral Sentiment: Additional coverage from Yahoo Finance and Seeking Alpha mainly recapped Moderna’s Science Day presentation and expanding mRNA platform, reinforcing the same positive narrative rather than adding a new standalone catalyst. Article Article
• Neutral Sentiment: One note on short interest reported unusual data showing zero shares, so it does not appear to be a meaningful driver of the move.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director directly owned 12,066 shares in the company, valued at $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,088 shares of company stock worth $6,193,713 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $67.27 on Friday. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $69.29. The company has a market cap of $26.69 billion, a PE ratio of -8.25 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The business has a 50-day simple moving average of $51.52 and a two-hundred day simple moving average of $46.50.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s revenue was up 260.2% compared to the same quarter last year. During the same quarter last year, the company earned ($2.52) EPS. As a group, equities analysts expect that Moderna, Inc. will post -6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Piper Sandler lifted their price objective on Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank Of Canada increased their target price on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a report on Monday, May 4th. Morgan Stanley set a $33.00 target price on shares of Moderna in a research report on Friday, May 1st. The Goldman Sachs Group boosted their price target on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna currently has an average rating of “Reduce” and a consensus price target of $37.13.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.